Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
- 1 August 2020
- journal article
- research article
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 24 (40), 1-190
- https://doi.org/10.3310/hta24400
Abstract
Health Technology Assessment Volume: 24, Issue: 40, Published in September 2020Funding Information
- Health Technology Assessment Programme (06/303/98)
This publication has 121 references indexed in Scilit:
- Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicinNature Communications, 2013
- Qualitative analysis of patients’ feedback from a PROMs survey of cancer patients in EnglandBMJ Open, 2013
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient careBritish Journal of Cancer, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoringBritish Journal of Cancer, 2009
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986